Promising Biotech Stocks To Add to Your Watchlist – April 20th

AbbVie, Thermo Fisher Scientific, Danaher, Vertex Pharmaceuticals, and IQVIA are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares in companies that develop products and technologies based on biological systems, often focusing on healthcare innovations like new drugs, therapies, and diagnostics. These stocks tend to offer high growth potential but can be volatile, as their success is closely linked to scientific breakthroughs, clinical trial outcomes, and regulatory approvals. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of ABBV stock traded up $1.10 on Friday, hitting $172.78. 8,474,425 shares of the stock traded hands, compared to its average volume of 6,005,419. The company has a debt-to-equity ratio of 17.94, a quick ratio of 0.55 and a current ratio of 0.66. The stock has a market capitalization of $305.64 billion, a PE ratio of 71.99, a PEG ratio of 1.62 and a beta of 0.55. The firm’s 50-day moving average price is $198.47 and its two-hundred day moving average price is $187.76. AbbVie has a twelve month low of $153.58 and a twelve month high of $218.66.

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

TMO traded down $10.68 on Friday, hitting $426.11. The company had a trading volume of 3,037,150 shares, compared to its average volume of 1,714,932. The firm has a market cap of $160.85 billion, a P/E ratio of 25.78, a PEG ratio of 2.99 and a beta of 0.86. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The company’s fifty day moving average price is $497.67 and its 200 day moving average price is $533.09. Thermo Fisher Scientific has a 1 year low of $409.85 and a 1 year high of $627.88.

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

NYSE:DHR traded down $3.95 during midday trading on Friday, reaching $186.71. The company had a trading volume of 3,667,685 shares, compared to its average volume of 3,329,253. The stock’s fifty day simple moving average is $201.99 and its 200-day simple moving average is $226.91. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. Danaher has a 12-month low of $171.00 and a 12-month high of $281.70. The firm has a market capitalization of $133.44 billion, a price-to-earnings ratio of 35.36, a PEG ratio of 2.66 and a beta of 0.86.

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Shares of Vertex Pharmaceuticals stock traded up $3.21 during trading hours on Friday, hitting $489.10. The company had a trading volume of 1,205,462 shares, compared to its average volume of 1,330,372. The company has a market cap of $125.60 billion, a P/E ratio of -222.32, a price-to-earnings-growth ratio of 2.11 and a beta of 0.50. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. Vertex Pharmaceuticals has a twelve month low of $377.85 and a twelve month high of $519.88. The company’s 50-day moving average is $486.76 and its two-hundred day moving average is $465.23.

IQVIA (IQV)

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

IQV traded down $4.78 during trading on Friday, reaching $143.66. 3,302,597 shares of the stock were exchanged, compared to its average volume of 1,408,683. The company has a market capitalization of $25.33 billion, a price-to-earnings ratio of 19.15, a P/E/G ratio of 1.99 and a beta of 1.46. IQVIA has a 1 year low of $135.97 and a 1 year high of $252.88. The business’s 50 day moving average price is $176.42 and its two-hundred day moving average price is $196.62. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.